NFKB1 and colorectal cancer: Interestingly, LXA4 treatment could obviously suppress p-ERK, p-P38 and NF-κB, suggesting that LXA4 may inhibit colorectal cancer and associated inflammation via modulating ERK, P38 and NF-κB pathways.